Summit Therapeutics plc (SMMT) EPS Estimated At $-0.76

May 17, 2018 - By Jimmy Baldridge

Summit Therapeutics plc (NASDAQ:SMMT) Logo

Analysts expect Summit Therapeutics plc (NASDAQ:SMMT) to report $-0.76 EPS on June, 13.They anticipate $0.26 EPS change or 52.00 % from last quarter’s $-0.5 EPS. After having $-1.15 EPS previously, Summit Therapeutics plc’s analysts see -33.91 % EPS growth. The stock increased 0.50% or $0.07 during the last trading session, reaching $13.96. About 37,526 shares traded. Summit Therapeutics plc (NASDAQ:SMMT) has risen 4.52% since May 18, 2017 and is uptrending. It has underperformed by 7.03% the S&P500.

Summit Therapeutics plc (NASDAQ:SMMT) Ratings Coverage

Among 8 analysts covering Summit Therapeutics plc – American Depositary Shares (NASDAQ:SMMT), 8 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Summit Therapeutics plc – American Depositary Shares had 10 analyst reports since December 1, 2017 according to SRatingsIntel. The stock has “Buy” rating by SunTrust on Friday, April 13. Canaccord Genuity maintained it with “Buy” rating and $28.0 target in Tuesday, March 6 report. Canaccord Genuity maintained the shares of SMMT in report on Wednesday, April 11 with “Buy” rating. On Friday, January 26 the stock rating was maintained by Oppenheimer with “Outperform”. H.C. Wainwright reinitiated the shares of SMMT in report on Friday, December 1 with “Buy” rating.

Summit Therapeutics plc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel medicines to treat genetic and infectious diseases in the United Kingdom and North America. The company has market cap of $218.88 million. It is conducting clinical programmes focused on the genetic disease Duchenne muscular dystrophy and the infectious disease Clostridium difficile infection (CDI). It currently has negative earnings. The companyÂ’s lead DMD product candidate is ezutromid, an orally administered small molecule, which is in Phase II clinical trial in patients with DMD; and lead CDI product candidate is ridinilazole, an orally administered small molecule antibiotic that has completed Phase II clinical trials for the treatment of CDI disease.

More notable recent Summit Therapeutics plc (NASDAQ:SMMT) news were published by: which released: “Summit Therapeutics plc : Director/PDMR Shareholding” on April 23, 2018, also with their article: “Summit Therapeutics plc : Total voting rights” published on May 01, 2018, published: “Summit Therapeutics (SMMT) Announces New 24-Week Analyses from PhaseOut DMD” on April 20, 2018. More interesting news about Summit Therapeutics plc (NASDAQ:SMMT) were released by: and their article: “Award of Share Options and Restricted Stock Units” published on April 23, 2018 as well as‘s news article titled: “Summit Highlights Discovery of a Series of New Mechanism Antibiotics for the Treatment of Gonorrhoea in Late …” with publication date: April 23, 2018.

Summit Therapeutics plc (NASDAQ:SMMT) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: